Previous 10 | Next 10 |
AlphaFold is a leading open-source AI program that aids researchers in visualizing protein structures. Applications are diverse and reduce research time across the healthcare industry and academia. The program certainly is a gift to our future health, but the open source nature an...
The following slide deck was published by Exscientia plc in conjunction with this event. For further details see: Exscientia (EXAI) Investor Presentation - Slideshow
Clinical data builds upon body of evidence suggesting EXS-21546 is a highly potent and selective A 2A R antagonist with low CNS exposure Exscientia anticipates initiating Phase 1b/2 in patients with high adenosine signature cancers in second half of 2022 Ongoing tr...
Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, and Dave Hallett, Chief Operations Officer, will participate in a fireside chat at the Goldman Sachs 43 rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 9:2...
Exscientia plc (EXAI) Q1 2022 Earnings Conference Call May 26, 2022 08:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Nikolaus Krall - Vice President of Precision Medicine Ben Taylor - Chief Financial Officer and Chie...
The following slide deck was published by Exscientia plc in conjunction with their 2022 Q1 earnings call. For further details see: Exscientia plc 2022 Q1 - Results - Earnings Call Presentation
Exscientia press release (NASDAQ:EXAI): Q1 GAAP EPS of -£0.41. Revenue of £9.2M (+31.4% Y/Y) misses by £23.2M. For further details see: Exscientia GAAP EPS of -£0.41, revenue of £9.2M misses by £23.2M
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for ...
Company to host conference call and webcast on May 26, 2022 at 1:30 p.m. BST / 8:30 a.m. ET Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will re...
Exscientia (Nasdaq: EXAI) today announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:20 p.m. P.T. A live webcast...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...